Tenax and Orion finalize supply pact and sixth amendment for oral levosimendan

Tenax Therapeutics disclosed in an 8-K that on June 29, 2026, it and Finland's Orion Corporation entered into a Supply Agreement covering the manufacture and supply of Tenax's orally administered levosimendan product. Under the companies' existing License Agreement, Orion has the right to be Tenax's primary supplier of the oral product for development and, if approved, commercial purposes.¹ Orion exercised that option, and the new agreement covers forecasting, ordering, delivery, quality, and pricing, plus terms for handling non-conforming product and certain rights for Tenax to use alternative manufacturers.¹ It also includes cost-sharing provisions related to expanding Orion's manufacturing capacity.¹

The agreement runs for an initial five years from the first delivery of the supplied product, renewing automatically in three-year terms unless either side gives 24 months' written notice that it will not renew.¹ Either company may terminate early for the other's uncured material breach after a 60-day cure period, for insolvency, or if the underlying License Agreement is terminated.¹ The full text of the Supply Agreement is expected to be filed with Tenax's upcoming quarterly report.¹

Separately, the companies signed a Sixth Amendment to their License Agreement, originally dated September 20, 2013 and previously amended in October 2020, January 2022, February 2024, October 2024, and September 2025.¹ The amendment moves to December 31, 2035 the deadline by which US regulatory approval must be obtained to prevent either party from being able to exercise a termination right tied to that milestone.¹ It also adds cybersecurity and information-security compliance requirements for Tenax under Orion's standards.¹ All other terms of the License Agreement remain in effect.¹